If only...
Pharmaceutical giant AstraZeneca (LSE: AZN) is expected to grow its earnings per share (EPS) in 2018, after four years of stagnant profits. Last month Astra reported that drug sales fell by 2% to $10bn (in constant currency terms) in the first half of 2018, while core operating profits were down 34% to $2.2bn. However, sales from new medicines rose by 69%, thanks largely to a strong performance from its cancer drugs including Tagrisso, which has benefited from its recent approval as the first-choice treatment for lung-cancer patients in Europe.
Be glad you didn't buy...
Mitie Group (LSE: MTO) provides services to owners and occupiers of commercial and industrial properties. The outsourcer, which was hit by several profit warnings and investigations by financial regulators last year, came under scrutiny after Carillion's collapse in January this year. However, in June it reported a pre-tax loss of £24.7m, down from £58.2m the previous year, while revenues rose 3.8% to £2.2bn. Mitie's chief executive Phil Bentley claims the firm's turnaround is on track and that it will return to profit this year as cost saving measures start to take effect.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
-
Act now: First Direct’s £175 switching bonus ending soon
First Direct has launched a £12,500 prize draw on top of its £175 cash bonus - but they both finish soon, so you’ll need to be quick
-
Credit card providers slash 0% balance transfer deals
Customers face a double whammy of rising interest rates and shorter 0% balance transfer periods. We look at what’s going on in the credit card market and why you’ll need to act fast to get the top 0% balance transfer deal
-
AstraZeneca’s Covid troubles could see it pull out of making vaccines
News AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
-
AstraZeneca’s shareholders rebel over pay
News Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
-
Major setback for AstraZeneca
Features Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
-
A revolutionary new cancer treatment – and the blue-chip stock set to benefit
Features A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
-
AstraZeneca fight rumbles on
News The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
-
Company in the news: AstraZeneca
Features Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
-
Buy Big Pharma – the deal spree could be just beginning
Features With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
